Literature DB >> 16782298

MEDICODE: an instrument to describe and evaluate exchanges on medications that occur during medical encounters.

Claude Richard1, Marie-Thérèse Lussier.   

Abstract

OBJECTIVE: To examine the psychometric properties of MEDICODE, a coding instrument developed to assess medication discussions during medical consultations.
METHODS: Inter-coder reliability, test-retest stability, and concurrent validity with the Roter Interaction Analysis System (RIAS) and predictive validity with the Medical Interview Satisfaction Scale (MISS) were calculated.
RESULTS: Inter-coder reliability and test-retest stability for medication class and status were both very good. Inter-coder agreement and test-retest stability for theme identification were mostly over 90%. Kappa values for theme identification varied from acceptable to excellent for 21 of the 29 and for 26 of the 37 Kappa coefficients that could be calculated. The mean percent agreement between MEDICODE and RIAS for medication class was of 96.8% and the mean Kappa value was 0.83. Although the mean percent agreement for the presence of a theme in MEDICODE and RIAS was 81%, the average Kappa coefficients were lower at 0.40. However, each of the four broad theme categories had its share of themes with robust Kappa values. We found significant positive correlations (p<0.05) between discussions of medication main effects and instructions with patient satisfaction.
CONCLUSION: With a reasonable amount of training, the coders were able to produce reliable and valid measures of discussions of medications during medical consultations. PRACTICAL IMPLICATIONS: MEDICODE will facilitate the study of the impact of the nature and intensity of discussions about medications during consultations on patient medication knowledge, medication recall and compliance.

Entities:  

Mesh:

Year:  2006        PMID: 16782298     DOI: 10.1016/j.pec.2006.02.002

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  7 in total

1.  Consumer satisfaction with antipsychotic medication-monitoring appointments: the role of consumer-prescriber communication patterns.

Authors:  Catherine M Reich; Samantha M Hack; Elizabeth A Klingaman; Clayton H Brown; Li Juan Fang; Lisa B Dixon; Danielle R Jahn; Julie A Kreyenbuhl
Journal:  Int J Psychiatry Clin Pract       Date:  2017-09-17       Impact factor: 1.812

2.  Prescribing new medications: a taxonomy of physician-patient communication.

Authors:  Derjung M Tarn; John Heritage; Debora A Paterniti; Ron D Hays; Richard L Kravitz; Neil S Wenger
Journal:  Commun Med       Date:  2008

3.  Deprescribing conversations: a closer look at prescriber-patient communication.

Authors:  Justin P Turner; Claude Richard; Marie-Thérèse Lussier; Marie-Eve Lavoie; Barbara Farrell; Denis Roberge; Cara Tannenbaum
Journal:  Ther Adv Drug Saf       Date:  2018-10-20

4.  Words that make pills easier to swallow: a communication typology to address practical and perceptual barriers to medication intake behavior.

Authors:  Annemiek J Linn; Julia Cm van Weert; Barbara C Schouten; Edith G Smit; Ad A van Bodegraven; Liset van Dijk
Journal:  Patient Prefer Adherence       Date:  2012-12-11       Impact factor: 2.711

5.  Evaluating holistic needs assessment in outpatient cancer care--a randomised controlled trial: the study protocol.

Authors:  Austyn Snowden; Jenny Young; Craig White; Esther Murray; Claude Richard; Marie-Therese Lussier; Ewan MacArthur; Dawn Storey; Stefano Schipani; Duncan Wheatley; Jeremy McMahon; Elaine Ross
Journal:  BMJ Open       Date:  2015-05-11       Impact factor: 2.692

6.  Communication and patient participation influencing patient recall of treatment discussions.

Authors:  Claude Richard; Emma Glaser; Marie-Thérèse Lussier
Journal:  Health Expect       Date:  2016-11-21       Impact factor: 3.377

7.  Development of a measurement system for complex oral information transfer in medical consultations.

Authors:  J M Nordfalk; P Gulbrandsen; J Gerwing; M Nylenna; J Menichetti
Journal:  BMC Med Res Methodol       Date:  2019-07-04       Impact factor: 4.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.